Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Augusto Jean-François

Augusto Jean-François

Université d’Angers, France

Title: Anti-Pentraxin 3 autoantibodies: a new maker of ANCA-associated vasculitisa new maker of ANCA-associated vasculitis

Biography

Biography: Augusto Jean-François

Abstract

Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) are a group of human life-threatening diseases characterized by multiorgan involvement. AAV diagnosis relies on the histological identification of small vessel vasculitis in an affected organ and on the identification of ANCA directed to myeloperoxidase (MPO) or proteinase 3 (PR3). ANCA detection allows a rapid diagnosis and the initiation of immunosuppressive treatments. However, up to 15% of affected patients are ANCA negatives, which frequently delays the treatment initiation. Pentraxin 3 (PTX3), such as MPO and PR3, is stored in human neutrophil granules and is expressed on apoptotic neutrophil surface. We therefore investigated the presence of anti-PTX3 autoantibodies (aAbs) in the sera of AAV patients, to evaluate the potential interest of this novel biological marker in the diagnosis of AAV. Presence of anti-PTX3 autoantibodies was analyzed by a specific ELISA in sera from 150 AAV patients and in sera of 227 healthy subjects (HS). Using indirect immunofluorescence on human fixed neutrophils, we also analyzed the staining pattern associated with the presence of anti-PTX3 aAbs. Anti-PTX3 aAbs were detected in 56 of 150 (37.3%) of the AAV patients (versus 12 of 227 (5.3%) of HS, p<0.001) and, interestingly, in 7 of 14 MPO and PR3 ANCA negative AAV patients. Moreover, by indirect immunofluorescence on fixed neutrophils, anti-PTX3 aAbs gave rise to a specific cytoplasmic fluorescence pattern distinct from the classical cytoplasmic (c-ANCA), perinuclear (p-ANCA), and atypical (a-ANCA) pattern. No association between anti-PTX3 aAb titers and disease activity was found. Anti-PTX3 aAbs appear thus as a promising novel biomarker in the diagnosis of AAV, especially in patients without detectable MPO and PR3 ANCA.